T1	p 61 101	patients with alcoholic liver disease --
T2	p 302 327	alcoholic liver disease .
T3	p 438 566	patients with alcoholic liver disease . Fifty patients with alcoholic liver disease ( 27 with cirrhosis , 23 without cirrhosis )
T4	p 896 917	15 healthy controls .
T5	p 1191 1209	healthy controls ,
T6	p 1587 1606	cirrhotics reported
T7	p 1688 1727	patients with alcoholic liver disease .
T8	i 31 42	paromomycin
T9	i 119 137	placebo-controlled
T10	i 223 245	gut-derived endotoxins
T11	i 378 419	nonabsorbable , broad-spectrum antibiotic
T12	i 601 629	either paromomycin sulfate (
T13	i 636 654	g/day ) or placebo
T14	i 935 957	paromomycin or placebo
T15	i 1125 1136	paromomycin
T16	i 1316 1329	( paromomycin
T17	i 1396 1417	paromomycin treatment
T18	i 1547 1568	paromomycin treatment
T19	o 46 57	endotoxemia
T20	o 423 434	endotoxemia
T21	o 740 776	concentration , liver function tests
T22	o 779 810	and other laboratory parameters
T23	o 849 872	Endotoxin concentration
T24	o 1032 1064	initial endotoxin concentrations
T25	o 1245 1273	mean endotoxin concentration
T26	o 1447 1494	endotoxin concentration or liver function tests
T27	o 1572 1583	endotoxemia